CAR-T– tag –
-
UCSD Advances Next-Gen CAR-T & Gamma Delta T-Cell Therapies for Solid Tumors in Multiple Phase 1 Clinical Trials
UCSD USA Overview UCSD is actively pursuing multiple Phase 1 clinical trials for next-generation cell therapies targeting advanced solid tumors. Featured trials include FT825/ONO-8250, an off-the-shelf HER2 CAR-T, and A2B395, an allogene... -
New CAR-T Engineering Strategies Target Solid Tumor Barriers: Leveraging Real-World Data & Manufacturing Innovations
ecancer International Overview Novel engineering strategies for CAR-T cell therapy against solid tumors are focusing on enhancing T-cell anti-tumor activity and overcoming microenvironmental barriers. Recent clinical results, such as int... -
USC Viterbi Engineers Develop Ultrasound-Guided SHIFTERS Technology to Reprogram Solid Tumors for CAR-T Efficacy
USC Viterbi School of Engineering USA Overview Researchers at the USC Viterbi School of Engineering have developed a novel technology called SHIFTERS to enable CAR-T cells to effectively target solid tumors. This method uses focused ultr... -
NueCell Bio Launches 26,300-Square-Foot Cell Therapy Development Facility to Scale CDMO Services in San Diego
PharmaSource USA Overview NueCell Bio has launched as a dedicated cell therapy science and development services company, opening a 26,300-square-foot facility in San Diego to support translational development, process development, analyt... -
Novartis’ CAR-T Cell Therapy Tisagenlecleucel Shows Durable Efficacy in Pediatric and Young Adult ALL
CancerNetwork USA Overview Novartis' CAR-T cell therapy, tisagenlecleucel (Kymriah), continues to demonstrate durable efficacy and safety in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia ... -
Groundbreaking CAR-T Cell Therapy Achievement: Multiple Myeloma Patient Attains Decade-Long Remission After Exhausting Chemotherapy Options
Stanford Medicine Facebook USA Overview A patient with advanced multiple myeloma achieved a remarkable 10-year remission after participating in a CAR-T cell therapy trial at the Fred and Pamela Buffett Cancer Center. Despite exhausting c... -
Clinical Progress of Engineered Cellular Immunotherapies for Autoimmunity: Diverse Modalities Pioneer New Treatment Avenues
PMC - NIH USA Overview Clinical development of engineered cellular immunotherapies for autoimmune diseases is rapidly advancing, poised to offer novel therapeutic options. Diverse modalities, including CAR-T cells, CAR-NK cells, and TCR-... -
In Vivo CAR-T Cell Therapy Achieves Clinical Proof of Concept; AI Integration Poised to Revolutionize Cancer Treatment
OncoDaily Unknown Overview In vivo CAR-T cell therapy has achieved initial clinical proof of concept, demonstrating its potential to transform cancer treatment. This novel approach directly delivers and expresses CAR genes in T-cells wit... -
CEA-Targeted CAR-NK Cells Derived from iPSCs Demonstrate Potent Anti-Tumor Activity Against Colorectal Cancer
Frontiers in Immunology Unknown Overview A new study reports that chimeric antigen receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) exhibit potent anti-tumor activity against colorectal cancer. These CEA-target... -
Allogene Therapeutics’ Off-the-Shelf CAR-T Cema-cel Achieves 58.3% MRD Negativity in ALPHA3 Phase 2 LBCL Trial, Securing FDA RMAT and Fast Track Designations
Allogene Therapeutics, Inc. (Press Release) USA Overview Allogene Therapeutics announced strong Q2 2026 results, highlighting that its off-the-shelf CAR T-cell therapy, cema-cel, achieved a robust 58.3% minimal residual disease (MRD) neg...
